Cargando…

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus

OBJECTIVES: The efficacy of belimumab (BEL) during maintenance therapy in patients with SLE remains unclear in the real-life clinical setting. This study investigated the efficacy and safety of BEL in patients with SLE during maintenance therapy. METHODS: In this retrospective observational study, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyazaki, Yusuke, Nakayamada, Shingo, Sonomoto, Koshiro, Kawabe, Akio, Inoue, Yoshino, Okubo, Naoaki, Iwata, Shigeru, Hanami, Kentaro, Tanaka, Yoshiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434316/ https://www.ncbi.nlm.nih.gov/pubmed/34962998 http://dx.doi.org/10.1093/rheumatology/keab953

Ejemplares similares

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study
por: Miyagawa, Ippei, et al.
Publicado: (2022)

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease
por: Miyagawa, Ippei, et al.
Publicado: (2019)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
por: Ueno, Masanobu, et al.
Publicado: (2021)

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
por: Kubo, Satoshi, et al.
Publicado: (2023)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus
por: Hao, He, et al.
Publicado: (2021)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
por: Ochi, Sae, et al.
Publicado: (2022)

Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus
por: Nakayamada, Shingo, et al.
Publicado: (2023)

Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus
por: Miyata, Mari, et al.
Publicado: (2017)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
por: Ueno, Masanobu, et al.
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus
por: Sakata, Kei, et al.
Publicado: (2018)

Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes
por: Miyagawa, Ippei, et al.
Publicado: (2022)

An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis
por: Ueno, Masanobu, et al.
Publicado: (2018)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes
por: Ueno, Masanobu, et al.
Publicado: (2022)

Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes
por: Ueno, Masanobu, et al.
Publicado: (2023)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry
por: Sonomoto, Koshiro, et al.
Publicado: (2021)

Enhancer RNA commits osteogenesis via microRNA-3129 expression in human bone marrow-derived mesenchymal stem cells
por: Nguyen, Anh Phuong, et al.
Publicado: (2022)

Epstein–Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor
por: Zhang, Tong, et al.
Publicado: (2022)

Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus
por: Iwata, Shigeru, et al.
Publicado: (2022)

High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus
por: Maeda, Shinji, et al.
Publicado: (2023)

Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
por: Zhou, Xuan, et al.
Publicado: (2021)

Belimumab in childhood systemic lupus erythematosus: A review of available data
por: Chen, Feng, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

B cell activation via immunometabolism in systemic lupus erythematosus
por: Iwata, Shigeru, et al.
Publicado: (2023)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
por: Cevey, Maria, et al.
Publicado: (2019)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
por: Roth, D A, et al.
Publicado: (2015)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
por: Sheikh, Saira Z., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_soltmkd5kk9bf7n1qbrodsfmgf